Effects of the probiotic formulation VSL#3 on colitis in weanling rats

Journal of Pediatric Gastroenterology and Nutrition

Volumn 44, Issue 5, 2007, Pages 561-570

  Fitzpatrick, Leo R ^a   Hertzog, Kristy L ^a   Quatse, Angela L ^a   Koltun, Walter A ^a   Small, Jeffrey S ^a   Vrana, Kent ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Colitis; Probiotics; Weanling rats

Indexed keywords

DEXTRAN SULFATE; DRINKING WATER; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL 3;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; COLITIS; COLON; CONTROLLED STUDY; CRYPT CELL; DESCENDING COLON; DEXTRAN SULFATE INDUCED COLITIS; DRUG EFFICACY; EXPERIMENTAL STUDY; FEEDING; FEMALE; HISTOLOGY; INTESTINE PARAMETERS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION; WEANING;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; I-KAPPA B PROTEINS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1BETA; MALE; PEROXIDASE; PROBIOTICS; RATS; RATS, WISTAR; WEANING;

ANIMALIA; RATTUS;

EID: 34247623042     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31803bda51     Document Type: Article

References (41)

1. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2000;20:459-549.
2. Byrne FR, Viney JL. Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Dev 2006;9:207-17.
3. Benno Y, Mitsuoka T. Development of intestinal microflora in humans and animals. Bifidobacteria Microflora 1986;5:13-25.
4. Mack DR, Neumann AW, Policova Z, et al. Surface hydrophobicity of the intestinal tract. Am J Physiol 1992;262:G171-7.
5. Shimizu T, Suzuki M, Fujimura J, et al. The relationship between the concentration of dextran sodium sulfate and the degree of induced experimental colitis in weanling rats. J Pediatr Gastroenterol Nutr 2003;37:481-6.
6. Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000;46:694-700.
7. Petrof EO, Kojima K, Ropeleski MJ, et al. Probiotics inhibit nuclear factor-κB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004;127:1474-87.
8. Shanahan F. Physiological basis for novel drug therapies to treat the inflammatory bowel diseases: I. Pathophysiological basis and prospects for probiotic therapy inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2004;288:G417-21.
9. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:286-99.
10. Araki Y, Andoh A, Takizawa J, et al. Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med 2004;13:577-80.
11. Osman N, Adawi D, Ahrne S, et al. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci 2004;49:320-7.
12. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
13. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-73.
14. DiGiacinto C, Marinaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10 dependent TGF-β-bearing regulatory cells. J Immunol 2005;174:3237-46.
15. Matarese LE, Seidner DL, Steiger E. The role of probiotics in gastrointestinal disease. Nutr Clin Pract 2003;6:507-16.
16. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999;48:137-43.
17. Egger B, Bajaj-Elliott M, MacDonald TT, et al. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000;62:240-8.
18. Gaudio E, Taddei G, Vetuschi A, et al. Dextran sulfate sodium (DSS) colitis in rats. Clinical, structural and ultrastructural aspects. Dig Dis Sci 1999;44:1458-75.
19. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
20. Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Animal 2000;49:9-15.
21. Di Giacinto C, Marinaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-meditaed murine colitis by inducing IL-10 and IL-10 dependent TGF-β bearing regulatory cells. J Immunol 2005;174:3237-46.
22. Calcinaro F, Dionisi S, Marinario M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005;48:1565-75.
23. Shibolet O, Karmeli F, Eliakim R, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002;8:399-406.
24. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
25. Murthy SNS, Cooper HS, Shim H, et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 1993;38:1722-34.
26. Williams KL, Fuller CR, Dieleman LA, et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001;120:925-37.
27. Krieglstein CF, Cerwinka WH, Laroux FS, et al. Role of appendix and spleen in experimental colitis. J Surg Res 2001;101:166-75.
28. Fitzpatrick LR, Khare V, Small JS, et al. Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide-2 (LMP2) expression and is attenuated in LMP2 knockout mice. Dig Dis Sci 2006;51:1269-76.
29. Fitzpatrick LR, Wang J, Le T. Gliotoxin, an inhibitor of nuclear factor-kappa B, attenuates peptidoglycan-polysaccharide-induced colitis in rats. Inflamm Bowel Dis 2002;8:159-67.
30. Fitzpatrick LR, Wang J, Le T. In vitro and in vivo effects of gliotoxin, a fungal metabolite: efficacy against dextran sodium sulfate-induced colitis in rats. Dig Dis Sci 2000;45:2327-36.
31. Vicario M, Crespi M, Franch A. Induction of colitis in young rats by dextran sulfate sodium. Dig Dis Sci 2005;50:143-50.
32. Murano M, Maemura K, Hirata I, et al. Therapeutic effect of intracolonically administered nuclear factor κB (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 2000;120:51-8.
33. Spiik AK, Ridderstad A, Axelsson LG, et al. Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 oligonucleotides. Int J Colorectal Dis 2002;17:223-32.
34. Jian YT, Mai GF, De Wang Y, et al. Preventative and therapeutic effects of nf-kappa B inhibitor curcumin in rat colitis induced by trinitrobenzenesulfonic acid. World J Gastroenterol 2005;11:1747-52.
35. Li JH, Yu JP, Yu HG, et al. Melatonin reduces inflammatory injury through inhibiting NF-κB activation in rats with colitis. Mediators Inflamm 2005;4:185-93.
36. Schottelius AJG, Baldwin AS. A role for transcription factor NF-κB in intestinal inflammation. Int J Colorect Dis 1999;14:18-28.
37. Jobin C, Sartor RB. NF-κB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 2000;6:206-13.
38. Jobin C, Sartor RB. The IκB/NF-κB system. a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000;278:C451-62.
39. Siegmund B. Interleukin-1β-converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 2002;64:1-8.
40. Loher F, Bauer C, Landauer N, et al. The interleukin-1β converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. JPET 2004;308:583-90.
41. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 2005;307:734-8.